Compared with RT alone, the tumors treated with therapeutic preparations containing radiosensitizer Hf and RT displayed the most severe DNA damage, accompanied by increased calreticulin (CRT) exposure and high mobility group box 1 (HMGB1) release (Figure 5A), which effectively improved tumor immunogenicity. Here, HMGB1 is linked to neoplasm.